42 related articles for article (PubMed ID: 18714521)
1. [The formation of infliximab and anti-infliximab immune complexes as an explanation for non-responding to infliximab treatment of rheumatoid arthritis: observational study in 4 patients].
van der Laken CJ; Voskuyl AE; Roos JC; Stigter van Walsum M; de Groot ER; Wolbink GJ; Dijkmans BA; Aarden LA
Ned Tijdschr Geneeskd; 2008 Jul; 152(30):1672-7. PubMed ID: 18714521
[TBL] [Abstract][Full Text] [Related]
2. Imaging and serum analysis of immune complex formation of radiolabelled infliximab and anti-infliximab in responders and non-responders to therapy for rheumatoid arthritis.
van der Laken CJ; Voskuyl AE; Roos JC; Stigter van Walsum M; de Groot ER; Wolbink G; Dijkmans BA; Aarden LA
Ann Rheum Dis; 2007 Feb; 66(2):253-6. PubMed ID: 16793840
[TBL] [Abstract][Full Text] [Related]
3. Formation, distribution, and elimination of infliximab and anti-infliximab immune complexes in cynomolgus monkeys.
Rojas JR; Taylor RP; Cunningham MR; Rutkoski TJ; Vennarini J; Jang H; Graham MA; Geboes K; Rousselle SD; Wagner CL
J Pharmacol Exp Ther; 2005 May; 313(2):578-85. PubMed ID: 15647331
[TBL] [Abstract][Full Text] [Related]
4. Increasing the infliximab dose in rheumatoid arthritis patients: a randomised, double blind study failed to confirm its efficacy.
Pavelka K; Jarosová K; Suchý D; Senolt L; Chroust K; Dusek L; Vencovský J
Ann Rheum Dis; 2009 Aug; 68(8):1285-9. PubMed ID: 19351624
[TBL] [Abstract][Full Text] [Related]
5. Analysis of apoptosis in peripheral blood and synovial tissue very early after initiation of infliximab treatment in rheumatoid arthritis patients.
Wijbrandts CA; Remans PH; Klarenbeek PL; Wouters D; van den Bergh Weerman MA; Smeets TJ; Vervoordeldonk MJ; Baeten D; Tak PP
Arthritis Rheum; 2008 Nov; 58(11):3330-9. PubMed ID: 18975323
[TBL] [Abstract][Full Text] [Related]
6. Treatment with infliximab plus methotrexate improves anemia in patients with rheumatoid arthritis independent of improvement in other clinical outcome measures-a pooled analysis from three large, multicenter, double-blind, randomized clinical trials.
Doyle MK; Rahman MU; Han C; Han J; Giles J; Bingham CO; Bathon J
Semin Arthritis Rheum; 2009 Oct; 39(2):123-31. PubMed ID: 18823645
[TBL] [Abstract][Full Text] [Related]
7. Correlation of CX3CL1 and CX3CR1 levels with response to infliximab therapy in patients with rheumatoid arthritis.
Odai T; Matsunawa M; Takahashi R; Wakabayashi K; Isozaki T; Yajima N; Miwa Y; Kasama T
J Rheumatol; 2009 Jun; 36(6):1158-65. PubMed ID: 19369458
[TBL] [Abstract][Full Text] [Related]
8. [T cell proliferative response and antibody formation to citrullinated collagen type II in patients with rheumatoid arthritis].
Tian X; Zhao Y; Li ZG
Zhonghua Yi Xue Za Zhi; 2009 Mar; 89(10):673-6. PubMed ID: 19595060
[TBL] [Abstract][Full Text] [Related]
9. [Treatment of rheumatoid arthritis (RA) with anti-TNF-alpha antibody (Remicade). Individual monitoring of bioavailability and immunogenicity--secondary publication].
Bendtzen K; Geborek P; Svenson M; Larsson L; Kapetanovic MC; Saxne T
Ugeskr Laeger; 2007 Jan; 169(5):420-3. PubMed ID: 17280636
[TBL] [Abstract][Full Text] [Related]
10. Infliximab improves vascular stiffness in patients with rheumatoid arthritis.
Wong M; Oakley SP; Young L; Jiang BY; Wierzbicki A; Panayi G; Chowienczyk P; Kirkham B
Ann Rheum Dis; 2009 Aug; 68(8):1277-84. PubMed ID: 18930987
[TBL] [Abstract][Full Text] [Related]
11. Prediction of efficacy of anti-TNF biologic agent, infliximab, for rheumatoid arthritis patients using a comprehensive transcriptome analysis of white blood cells.
Tanino M; Matoba R; Nakamura S; Kameda H; Amano K; Okayama T; Nagasawa H; Suzuki K; Matsubara K; Takeuchi T
Biochem Biophys Res Commun; 2009 Sep; 387(2):261-5. PubMed ID: 19577537
[TBL] [Abstract][Full Text] [Related]
12. Outside-to-inside signaling through transmembrane tumor necrosis factor reverses pathologic interleukin-1beta production and deficient apoptosis of rheumatoid arthritis monocytes.
Meusch U; Rossol M; Baerwald C; Hauschildt S; Wagner U
Arthritis Rheum; 2009 Sep; 60(9):2612-21. PubMed ID: 19714631
[TBL] [Abstract][Full Text] [Related]
13. The tumor necrosis factor-{alpha}-blocking agent infliximab inhibits interleukin 1beta (IL-1beta) and IL-6 gene expression in human osteoblastic cells.
Musacchio E; Valvason C; Botsios C; Ostuni F; Furlan A; Ramonda R; Modesti V; Sartori L; Punzi L
J Rheumatol; 2009 Aug; 36(8):1575-9. PubMed ID: 19567627
[TBL] [Abstract][Full Text] [Related]
14. Dose escalation of infliximab therapy in arthritis patients is related to diagnosis and concomitant methotrexate treatment: observational results from the South Swedish Arthritis Treatment Group register.
Kristensen LE; Geborek P; Saxne T
Rheumatology (Oxford); 2009 Mar; 48(3):243-5. PubMed ID: 19106164
[TBL] [Abstract][Full Text] [Related]
15. The role of anti-mutated citrullinated vimentin antibodies in the diagnosis of early rheumatoid arthritis.
Liu X; Jia R; Zhao J; Li Z
J Rheumatol; 2009 Jun; 36(6):1136-42. PubMed ID: 19447936
[TBL] [Abstract][Full Text] [Related]
16. An open-label pilot study of infliximab therapy in diffuse cutaneous systemic sclerosis.
Denton CP; Engelhart M; Tvede N; Wilson H; Khan K; Shiwen X; Carreira PE; Diaz Gonzalez F; Black CM; van den Hoogen FH
Ann Rheum Dis; 2009 Sep; 68(9):1433-9. PubMed ID: 18782794
[TBL] [Abstract][Full Text] [Related]
17. Influence of variants of Fc gamma receptors IIA and IIIA on the American College of Rheumatology and European League Against Rheumatism responses to anti-tumour necrosis factor alpha therapy in rheumatoid arthritis.
Cañete JD; Suárez B; Hernández MV; Sanmartí R; Rego I; Celis R; Moll C; Pinto JA; Blanco FJ; Lozano F
Ann Rheum Dis; 2009 Oct; 68(10):1547-52. PubMed ID: 18930989
[TBL] [Abstract][Full Text] [Related]
18. [Efficacy of treatment with infliximab in patients with moderate-severe psoriasis and high needs of therapy. A retrospective study of 43 patients].
Puig L
Actas Dermosifiliogr; 2008 Jul; 99 Suppl 4():30-5. PubMed ID: 19080989
[TBL] [Abstract][Full Text] [Related]
19. The DERAA HLA-DR alleles in patients with early polyarthritis: protection against severe disease and lack of association with rheumatoid arthritis autoantibodies.
Carrier N; Cossette P; Daniel C; de Brum-Fernandes A; Liang P; Ménard HA; Boire G
Arthritis Rheum; 2009 Mar; 60(3):698-707. PubMed ID: 19248090
[TBL] [Abstract][Full Text] [Related]
20. Depletion of B lymphocytes in rheumatoid arthritis patients modifies IL-8-anti-IL-8 autoantibody network.
Keren Z; Braun-Moscovici Y; Markovits D; Rozin A; Nahir M; Balbir-Gurman A; Melamed D
Clin Immunol; 2009 Oct; 133(1):108-16. PubMed ID: 19632157
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
